Stocktoria
Vir Biotechnology, Inc. VIR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-11
Vir Biotechnology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.6B | $1.1B |
| R&D expense | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M |
| SG&A expense | $92.1M | $119.0M | $174.4M | $161.8M | $160.8M |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M |
| Income tax | $217,000 | -$1.1M | -$13.1M | $238.4M | $21.2M |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M | $528.6M |
| EPS (diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 |
| Operating cash flow | -$391.8M | -$446.4M | -$778.8M | $1.7B | -$47.6M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.6B | -$69.4M |
| Cash & equivalents | $232.2M | $222.9M | $241.6M | $848.6M | $347.8M |
| Total assets | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M |
| Shareholders' equity | $765.3M | $1.2B | $1.6B | $2.1B | $1.4B |
Source: SEC EDGAR filings · CIK 0001706431 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.